Discontinuation rate of dual antiretroviral therapy with dolutegravir plus lamivudine in people living with HIV: a systematic review. RSD [Internet]. 2022 Sep. 19 [cited 2025 Dec. 6];11(12):e430111234758. Available from: https://rsdjournal.org/rsd/article/view/34758